Loading clinical trials...

Randomized Trial of Follow-up Strategies in Breast Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Randomized Trial of Follow-up Strategies in Breast Cancer

A Randomized Trial of Follow-up Strategies in Breast Cancer

NCT00156039•Ontario Clinical Oncology Group (OCOG)

Summary

The purpose of this study is to determine whether family physician 'routine follow-up care' of women with breast cancer in remission is an acceptable alternative to the existing system of specialist follow-up. Primary outcome measure are event rates of oncological catastrophes and quality of life.

Detailed Description

see above

Eligibility

Age

All ages

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Women with breast cancer on well follow-up at regional cancer centres in Ontario and Manitoba
•Diagnosed at least 12 months previously (range 9-15 months)
•Without evidence of active disease (i.e., stages IIIB and IV excluded)
•Free from any primary treatment complications

Exclusion Criteria

•Primary treatment at least 3 months previously, except for continued use of tamoxifen
•Still experiencing complications of primary treatment (patients will become eligible once complications resolve provided they are within the 6 month window)
•Unable to identify an acceptable family physician to provide follow-up
•Language or literacy skills inconsistent with completing questionnaires
•Unable to comply with study protocol including completion of questionnaires
•Previously enrolled in a study which requires continued follow-up in specialist or peripheral clinics
•Actively followed at a cancer centre for another primary cancer

Locations (5)

Juravinski Cancer Centre

Hamilton, Ontario, Canada

Kingston Regional Cancer Centre

Kingston, Ontario, Canada

Ottawa Hospital - Integrate Cancer Program

Ottawa, Ontario, Canada

Thunder Bay Regional Health Sciences Centre

Thunder Bay, Ontario, Canada

Toronto Sunnybrook Hospital

Toronto, Ontario, Canada

Key Dates

Start Date

January 1, 1997

Completion Date

June 1, 2003

Last Updated

July 28, 2009

Enrollment

968

ACTUAL participants

Conditions

Breast Cancer

Interventions

Follow-up Strategy for Breast Cancer

BEHAVIORAL

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 28, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Randomized Trial of Follow-up Strategies in Breast Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer